Camlin Fine Sciences is a specialty chemistry company that produces vanillin and ethyl vanillin (synthetic vanilla flavouring) plus customised antioxidant blends for food, feed and industrial customers, with a now-mothballed diphenol intermediate plant that had supplied feedstock internally. The money is made in two places: the Aroma vertical, where a 6,000-tonne-per-year vanillin plant converts catechol and hydroquinone into methyl and ethyl vanillin, and the Blends vertical, an asset-light formulation business that mixes antioxidants to customer specifications and reached an INR1,050 crore revenue base in FY26 including discontinued Europe activity. The niche is concentrated: anti-dumping duties of 250% on Chinese vanillin in the US and Europe, with Syensqo as the main disciplined price setter, leave Camlin one of a handful of qualified suppliers. That concentration has not yet translated into margins: Q1 FY27 EBITDA was about 4%, Q4 FY26 was 5%, and FY26 ended with mid-single-digit profitability because vanillin plant utilisation ran near 25-50% while raw material and freight costs spiked. The persistence of this low margin is the whole investment question.
The economics can persist if the qualification and tariff structure holds. Camlin's ethyl vanillin campaign of 700 tonnes in the latest quarter achieved 95% customer approval, and customers must revalidate each new campaign, creating switching friction. The US tariff reduction from 50% to 25% on Indian vanillin improves realisations from roughly $12.5 to $13.5-14 per kg, while Chinese competition is effectively locked out of the US and Europe by duties. Blends are a knowledge business where Camlin has invested 21% more sales personnel and where geographies such as Mexico and the US already generate 14-17% EBITDA margins. This is not an unassailable moat: local Indian competition in TBHQ and BHA has pushed prices down from $8.5-9 to around $7, and Chinese vanillin sells at $7-7.5 in unprotected markets, so Camlin cannot price above Syensqo's $17-18 DDP US level. The barrier is real in the core vanillin market, but it is regulatory and qualification based rather than proprietary technology.
The inflection is underway. In Q1 FY27, Camlin completed 350 tonnes of a planned 700-tonne ethyl vanillin campaign, 300 tonnes of orders were already pre-booked, and the next methyl vanillin campaign of 500-600 tonnes supports the full-year Aroma volume target of around 3,000 tonnes, while management still expects realisation of $13.5-14 per kg. Meanwhile, the Blends business crossed INR100 crore of monthly global revenue in the first month of FY27, and the Vinpai and Vitafor acquisitions are expected to grow 40-50% in FY27 after Vinpai went from INR10 crore to INR17 crore in its first three months. Eighteen to twenty-four months from now, if the current plan holds, Camlin should be running vanillin at 60-70% of its 6,000-ton capacity, selling 4,000-5,000 tonnes annually, with the diphenol plant either restarted in a higher-value use or permanently repurposed, and the European and Chinese loss-making operations fully wound down. That translates to revenue of INR2,200-2,400 crore in FY27 and potentially above INR2,400 crore in FY28, with EBITDA margins recovering to 12-14% as fixed costs are absorbed and the Blends mix shifts toward higher-margin custom formulations.
Management's track record is mixed, so the walk-talk test matters. On earlier calls they promised FY26 vanillin volumes of 2,500-3,000 tonnes and 18-20% Blends growth; nine-month actuals were about 1,740 tonnes and 11-13% Blends growth, so those operational commitments were missed. More recently, they held FY27 revenue guidance at INR2,200-2,300 crore but revised FY27 EBITDA margin guidance down to 10-12% from an earlier 12-14%, acknowledging raw material and freight headwinds in Q1. On delivery, they have met the discontinued-operations cash-burn target of INR8-9 crore per quarter, and they explicitly committed to having Aroma and Performance Chemicals EBITDA positive in Q2 FY27 and company-level double-digit EBITDA from Q3 FY27. Capital allocation leans on debt: gross debt is around INR640 crore, working capital is roughly 100 days, and management expects to add INR100-200 crore of credit lines while treating equity as a last resort. The Europe liquidation has already removed an annual cash burn of INR50-60 crore, and the China liquidation should cost no more than INR7-8 crore in FY27.
The earnings path is quantifiable: from a Q1 FY27 EBITDA margin of roughly 4%, management expects Q2 to be materially better, Q3 to cross into double digits, and the full year to land at 10-12% EBITDA, with a normalized 12-14% possible by FY28 if raw material prices settle and utilisation climbs. For that to happen, vanillin volumes must ramp from the current 500-600 tonnes per quarter to more than 1,000 tonnes in Q3 FY27, realisation must hold above $13.5 per kg, and Blends must sustain 20% growth without additional working capital strain. The single most important falsifier is the Q3 FY27 margin and volume print: if company-level EBITDA does not reach double digits while vanillin sales pass 1,000 tonnes, the 12-14% normalized margin thesis is not credible. A second watchpoint is liquidity, since the business needs roughly INR600 crore of working capital for an INR1,800 crore revenue base and is using higher-cost dealer financing; any further elongation of shipping routes or delay in raw material cost pass-through would push the recovery out by several quarters. The tension in the data, lower current profitability against higher guided margins, is operational rather than structural, but it depends on commodity prices, tariff stability and flawless execution of the campaigns already announced.
companyname: Camlin Fine Sciences Limited ticker: CAMLINFINE sector: Specialty Chemicals Camlin Fine Sciences Limited (CFS) is an integrated specialty chemicals manufacturer that makes antioxidants, aroma chemicals, and their downstream derivatives largely for the food, animal nutrition, and flavor & fragrance industries. The company was incorporated in 1993, is headquartered in Mumbai, and serves over 1,300 customers across more than 80 countries as of FY2026 (Annual Report FY2026). Group-leve...
Read the full report →margin expansion, regulatory approval, order book surge, acquisition inorganic
FY27 Blends revenue guided at INR1,400 crores driven by sales force expansion and product expansion; FY27 revenue guided at INR2,200-2,400 crores with EBITDA margins of 12-14% driven by Vanillin realization improvements and Blends growth
Guidance upgradedmixed
Get valuation models, detailed research reports, thematic primers, one-pagers, risk analysis, growth triggers, bear case, capex tracker, walk the talk, and more for Camlin Fine Sciences Limited and 4,900+ companies.
5-day free pass. No card required.